Gene chip technology for detecting mycobacteria and Mycobacterium tuberculosis resistance of isoniazid and rifampin in the application of tuberculous empyema / 中国人兽共患病学报

ABSTRACT

To evaluate the clinical value of gene chip technology (GCT) in detecting the mycoba-cteria,isoniazid and rifampin resistance of patients diagnosed tuberculous empyema.The 182 patients who met the inclusion criteria were enrolled to this study from January 2011 to December 2015,whose pus mycobacterial species were detected by GCT and MGIT,the simultaneous and sensitivity of them were compared.Meanwhile,36 patients diagnosed tuberculous empyema were selected to detect isoniazid and rifampin resistance.The simultaneous and sensitivity of GCT were evaluated base on the standard of MGIT.The 135 patients were diagnosed by tuberculous empyema.The specificity of GCT was same to MGIT (95.7％),the the sensitivity was 48.9％ (66/135)in GCT,26.7％ in MGIT,there was significant difference between them (x2=80.5,P＜ 0.05).The sensitivity,specificity and coincidence rate of GCT in rifampin resistance were 100％,the sensitivity,specificityand coincidence rate in INH were 50.0％(1/2),97.1％(33/34) and 94.4％.Gene chip technology for detection of mycobacteria has high sensitivity and specificity,which can identify non-tuberculous mycobacteria quickly.And it can also effectively detect the resistance of Mycobacterium tuberculosis to isoniazid and rifampicin.It has important significance in early diagnosis and treatment of tuberculous empyema.